HCPCS Level II code J9202 denotes goserelin acetate implant, per 3.6 mg, a GnRH agonist delivered as a subcutaneous implant for endocrine suppression in oncology and other hormone‑sensitive conditions. This national code is used to bill the implantable drug component of care where the product is provided to the patient, and it matters for consistent drug reporting, payer coverage decisions, and provider reimbursement across outpatient settings.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of goserelin implants, typical sites of service, common billing modifiers, and the role of HCPCS Level II coding in documenting drug implants. The publication also highlights benchmarks and policy considerations relevant to coverage and claims processing, and points to where additional clinical and billing details are typically found.

This summary is written for a national audience and focuses on code definition, operational implications for outpatient administration, and payer coverage context. Data not available in the input is noted where applicable in detailed sections.